Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
Phase 2
Suspended
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: 0.075 mg RVX-100Drug: 0.125 mg RVX-100Drug: 0.250 mg RVX-100Drug: placebo
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Revogenex, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT01076699
- Locations
- 🇺🇸
Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States
News
No news found